comparemela.com

Latest Breaking News On - Imcyse imotope - Page 1 : comparemela.com

DGAP-News: Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth

DGAP-News: Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.

Imcyse Raises Additional EUR 21 3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder

Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement Major existing shareholders participated in the round Proceeds to advance Imcyse’s pipeline of first-in-class targeted disease modifying immunotherapeutics Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of … Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement Major existing shareholders participated in the round Proceeds to advance Imcyse’s pipeline of first-in-class targeted disease modifying immunotherapeutics Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced that it has concluded a Series B extension financing round, raising EUR 21.3 million (USD 25.8 milli

DGAP-News: Imcyse Raises Additional EUR 21 3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder

DGAP-News: Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder vom 17.02.2021, 14:00 Uhr Bild: pixabay.com DGAP-News: Imcyse SA / Key word(s): Financing Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder 17.02.2021 / 14:00 The issuer is solely responsible for the content of this announcement. Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement Major existing shareholders participated in the round Proceeds to advance Imcyse s pipeline of first-in-class targeted disease modifying immunotherapeutics

Investegate |Imcyse SA Announcements | Imcyse SA: Imcyse Raises Additional EUR 21 3 Million in Series B Financing Round

Investegate |Imcyse SA Announcements | Imcyse SA: Imcyse Raises Additional EUR 21 3 Million in Series B Financing Round
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis | More News

Hits: 1464 Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis • Imcyse and Pfizer to collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis  • Pfizer to lead clinical development and commercialization activities • Imcyse to receive upfront payment in cash and through the purchase of equity in addition to milestone up to $180 million and tiered royalty payments   LIEGE, Belgium I February 03, 2021 I Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced that it has entered into a research collaboration and license agreement with Pfi

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.